The Use of Complementary and Alternative Medicine in Prostate Cancer Patients

Oncology Issues

Volumn 15, Issue 6, 2000, Pages 23-27

  Woo, Eunhee W ^a   Quinn, Mary ^a   Figg, William D ^a   Dahut, William ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0002990635     PISSN: 10463356     EISSN: 25731777     Source Type: Journal    
DOI: 10.1080/10463356.2000.11905172     Document Type: Article

References (47)

1. Ernst E, Cassileth BR. The prevalence of complementary/alternative medicine in cancer: a systematic review. Cancer. 1998;83:777–82.
2. Cassileth BR. Complementary and alternative cancer medicine. J Clin Oncol. 1999;17(suppl):44–52.
3. Richardson MA, Sanders T, Palmer JL, et al. Complementary/alternative medicine use in a comprehensive cancer center and the implications for oncology. J Clin Oncol. 2000;18:2505–14.
4. Nam RK, Fleshner N, Rakovitch E, et al. Prevalence and patterns of the use of complementary therapies among prostate cancer patients: an epidemiological analysis. J Urol. 1999;161:1521–24.
5. Moyad MA, Pienta KJ, Montie JS. Use of PC-SPES, a commercially available supplement for prostate cancer, in a patient with hormone-naive disease. Urol. 1999;54:319–23.
6. DiPaola RS, Zhang H, Lambert GH, et al. Clinical and biologic activity of an estrogenic herbal combination (PCSPES) in prostate cancer. N Engl J Med. 1998;339:785–91.
7. Kameda H, Small EJ, Reese DM, et al. A phase II study of PC-SPES, an herbal compound, for the treatment of advanced prostate cancer. American Society of Clinical Oncology; 1999. Abstract 1230.
8. Small EJ, Corry M, Frohlich MA, et al. Effects of PC-SPES, an herbal compound, in patients with androgen dependent prostate cancer. American Society of Clinical Oncology; 2000. Abstract 1316.
9. Kubota T, Hisatake J, Hisatake Y, et al. PC-SPES: a unique inhibitor of proliferation of prostate cancer cells in vitro and in vivo. Prostate. 2000;42:163–71.
10. Halicka HD, Ardelt B, Juan G, et al. Apoptosis and cell cycle effects induced by extracts of the Chinese herbal preparation PC-SPES. Int J Oncol. 1997;11:437–48.
11. Hsieh T, Ng C, Chang C, et al. Induction of apoptosis and down-regulated of bcl-6 in Mutu I cells treated with ethanolic extracts of the Chinese herbal supplement PC-SPES. Int J Oncol. 1998;13:1199–202.
12. Hsieh T, Chen S, Wang X, et al. Regulation of androgen receptor (AR) and prostate specific antigen (PSA) expression in the androgen-responsive human prostate LNCaP cells by ethanolic extracts of the Chinese herbal preparation, PC-SPES. Biochem Mol Biol Int. 1997;42:535–44.
13. Pfeifer BL, Pirani JF, Hamann SR, et al. PC-SPES, a dietary supplement for the treatment of hormone-refractory prostate cancer. BJU Int. 2000; 85:481–85.
14. William KO, Daniel JG, Philip WK. Activity of the herbal combination, PC-SPES, in androgen-independent (AI) prostate cancer (PC) patients. American Society of Clinical Oncology; 2000. Abstract 1334.
15. The Leuprolide Study Group. Leuprolide versus diethylstilbestrol for metastatic prostate cancer. N Engl J Med. 1984;311:1281–86.
16. Citrin DL, Kies MS, Wallemark CB, et al. A phase II study of high-dose estrogens (diethylstilbestrol diphosphate) in prostate cancer. Cancer. 1985;56:457–60.
17. Institute of Medicine, National Academy of Sciences, Food and Nutrition Board, Panel on Dietary Antioxidants and Related Compounds. Dietary reference intakes for vitamin C, vitamin E, selenium, and carotenoids. Washington, DC: National Academy Press; 2000.
18. Moyad MA, Brumfield SK, Pienta KJ. Vitamin E, alpha- and gammatocopherol, and prostate cancer. Semin Urol Oncol. 1999;17:85–90.
19. Meydani M, Vitamin E. Lancet. 1995;345:170–75.
20. Fleshner N, Fair WR, Huryk R, Heston WD. Vitamin E inhibits the high-fat diet promoted growth of established human prostate LNCaP tumors in nude mice. J Urol. 1999;161:1651–54.
21. Sigounas G, Anagnostou A, Steiner M. Dl-alpha-tocopherol induces apoptosis in erythroleukemia, prostate, and breast cancer cells. Nutr Cancer. 1997;28:30–35.
22. Heinonen OP, Albanes D, Virtamo J, et al. Prostate cancer and supplementation with alpha-tocopherol and beta-carotene: incidence and mortality in a controlled trial. J Natl Cancer Inst. 1998;90:440–46.
23. Willett WC, Polk BF, Morris JS, et al. Prediagnostic serum selenium and risk of cancer. Lancet. 1983;2:130–34.
24. Yoshizawa K, Willett WC, Morris SJ, et al. Study of prediagnostic selenium level in toenails and the risk of advanced prostate cancer. J Natl Cancer Inst. 1998;90:1219–24.
25. Combs GF, Jr, Gray WP. Chemopreventive agents: selenium. Pharmacol Ther. 1998;79:179–92.
26. Fox JM. Selenium: nutritional implications and prospects for therapeutic medicine. Methods Find Exp Clin Pharmacol. 1992;14(4):275–87.
27. Horvath PM, Ip C. Synergistic effect of vitamin E and selenium in the chemoprevention of mammary carcinogenesis in rats. Cancer Res. 1983;43:5335–41.
28. Takada H, Hirooka T, Hatano T, et al. Inhibition of 7,12-dimethylbenz-[a]anthracene-induced lipid peroxidation and mammary tumor development in rats by vitamin E in conjunction with selenium. Nutr Cancer. 1992;17:115–22.
29. Clark LC, Combs GF, Jr, Turnbull BW, et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA. 1996;276:1957–63.
30. Brawley OW, Parnes H. Prostate cancer prevention trials in the USA. Eur J Cancer. 2000;36:1312–15.
31. Mayne ST, Vogt TM. Antioxidant nutrients in cancer prevention. PPO Updates. 2000;14:1–12.
32. Nelson MA, Porterfield BW, Jacobs ET, et al. Selenium and prostate cancer prevention. Semin Urol Oncol. 1999;17:91–96.
33. Schrauzer GN, White DA. Selenium in human nutrition: dietary intakes and effects of supplementation. Bioinorg Chem. 1978;8:303–18.
34. Longnecker MP, Stram DO, Taylor PR, et al. Use of selenium concentration in whole blood, serum, toenails, or urine as a surrogate measure of selenium intake. Epidemiol. 1996;7:384–90.
35. Giovannucci E. Tomatoes, tomato-based products, lycopene, and cancer: review of the epidemiologic literature. J Natl Cancer Inst. 1999;91:317–31.
36. Clinton SK, Emenhiser C, Schwartz SJ, et al. Cis-trans lycopene isomers, carotenoids, and retinol in the human prostate. Cancer Epidemiol Biomarkers Prev. 1996;5:823–33.
37. Norrish AE, Jackson RT, Sharpe SJ, et al. Prostate cancer and dietary carotenoids. Am J Epidemiol. 2000; 151:119–23.
38. Lamson DW, Brignall MS. Antioxidants in cancer therapy; their actions and interactions with oncologic therapies. Altern Med Rev. 1999; 4:304–29.
39. Adlercreutz H, Markkanen H, Watanabe S. Plasma concentrations of phyto-oestrogens in Japanese men. Lancet. 1993;342:1209–10.
40. Davis JN, Kucuk O, Sarkar FH. Genistein inhibits NF-kappa B activation in prostate cancer cells. Nutr Cancer. 1999;35:167–74.
41. Hebert JR, Hurley TG, Olendzki BC, et al. Nutritional and socioeconomic factors in relation to prostate cancer mortality: a cross-national study. J Natl Cancer Inst. 1998; 90:1637–47.
42. Griffiths K, Morton MS, Denis L. Certain aspects of molecular endocrinology that relate to the influence of dietary factors on the pathogenesis of prostate cancer. Eur Urol. 1999;35:443–55.
43. Iehle C, Delos S, Guirou O, et al. Human prostatic steroid 5 alpha-reductase isoforms—a comparative study of selective inhibitors. J Steroid Biochem Mol Biol. 1995;54:273–79.
44. Weisser H, Tunn S, Behnke B, et al. Effects of the sabal serrulata extract IDS 89 and its subfractions on 5 alpha-reductase activity in human benign prostatic hyperplasia. Prostate. 1996;28:300–06.
45. Wilt TJ, Ishani A, Stark G, et al. Saw palmetto extracts for treatment of benign prostatic hyperplasia: a systematic review. JAMA. 1998;280:1604–09.
46. Plosker GL, Brogden RN. Serenoa repens (Permixon). A review of its pharmacology and therapeutic efficacy in benign prostatic hyperplasia. Drugs Aging. 1996;9:379–95.
47. Carraro JC, Raynaud JP, Koch G, et al. Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1,098 patients. Prostate. 1996;29:231–40.